Lexaria Bioscience Corp.
For the period ended Jan 27, 2026. Filed Dec 10, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jan 27, 2026 · Filed Dec 10, 2025
Contents
Pay vs Performance
Pay Versus Performance
In accordance with rules adopted by the Securities and Exchange Commission pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, we are providing the following table outlining the past three fiscal years’ executive compensation for our principal executive officer (“PEO”) and Non-PEO executive officers (“NEOs”) and comparative Company performance based on total shareholder return. We are a smaller reporting company (“SRC”), as defined in Rule 12b-2 under the Exchange Act and have elected to provide in this proxy statement certain scaled disclosures permitted under the Exchange Act for SRCs
| Fiscal Year(a) | Summary CompensationTable for PEO(1)(b) | Compensation Actually Paid to PEO(2)(3)(c) | Average Summary CompensationTable Totals ForNon-PEO NEOs(1)(d) | Average Compensation Actually Paid to Non-PEO NEOs(2)(3)(e) | Value of Initial Fixed $100 Investment Based on Total Shareholder Return (f) (4) | Net Income (or Loss)(g) |
|---|---|---|---|---|---|---|
| 2025 | $893,302 | $496,747 | $385,947 | $279,558 | $(77.49) | $(11,911,434) |
| 2024 | $1,404,161 | $1,669,179 | $296,331 | $340,452 | $272.38 | $(5,808,654) |
| 2023 | $287,632 | $156,939 | $237,188 | $140,476 | $(64.53) | $(6,712,525) |
| (1) | The PEO reflects Chris Bunka, who served as the Company’s CEO until August 31, 2024 and Richard Christopher, the Company’s current CEO. The Non-PEO NEOs noted are John Docherty, the Company’s President & CSO, Michael Shankman, the Company’s current CFO, Nelson Cabatuan, the Company’s CFO from March 2024 to July 2024 and Greg Downey, the Company’s CFO from April 2021 to June 2023; |
| (2) | The amounts shown in the Compensation Actually Paid have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually realized or received, but rather reflect compensation as set forth in the Summary Compensation Table for each year, adjusted as described in footnote 3 below; |
| (3) | Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEO and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718; |
| (4) | As we have not paid any dividends, cumulative TSR is calculated by dividing $100 by the last closing price in fiscal 2020 to obtain a number of shares, and multiplying that number of shares by the closing price on the last trading day of the relevant measure period. |
| PEOsPrior FYECurrent FYEFiscal Year | 08/31/202308/31/20242024 (1) | 08/31/202408/31/20252025 (1) |
|---|---|---|
| SCT Total | 1,404,161 | 893,302 |
| Minus Grant Date Fair Value of Options Awards Granted in Fiscal Year | 599,391 | 317,019 |
| Plus Fair Value at FYE of Outstanding and Unvested Option Awards Granted in Fiscal Year | 598,485 | 72,702 |
| Plus Change in Fair Value of Outstanding and Unvested Option Awards Granted in Prior Fiscal Years | 186,843 | (469,257) |
| Plus Fair Value at Vesting of Option Awards Granted in Fiscal Year That Vested During Fiscal Year | 79,081 | 317,019 |
| Plus Changes in Fair Value as of Vesting Date of Option Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year | - | - |
| Minus Fair Value as of Prior Fiscal Year-End of Option Awards Granted in Prior Fiscal Years that Failed to Meet Applicable Vesting Conditions During Fiscal Year | - | - |
| Compensation Actually Paid | 1,669,179 | 496,747 |
(1) The 2024 and 2025 fiscal years reflect the combined values for Chris Bunka and Richard Christopher.
| NEOsPrior FYECurrent FYEFiscal Year | 08/31/202308/31/20242024 | 08/31/202408/31/20252025 |
|---|---|---|
| SCT Total | 296,331 | 385,947 |
| Minus Grant Date Fair Value of Options Awards Granted in Fiscal Year | 162,791 | 105,097 |
| Plus Fair Value at FYE of Outstanding and Unvested Option Awards Granted in Fiscal Year | 55,939 | 55,258 |
| Plus Change in Fair Value of Outstanding and Unvested Option Awards Granted in Prior Fiscal Years | 91,004 | (118,563) |
| Plus Fair Value at Vesting of Option Awards Granted in Fiscal Year That Vested During Fiscal Year | 59,969 | 62,013 |
| Plus Changes in Fair Value as of Vesting Date of Option Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year | - | - |
| Minus Fair Value as of Prior Fiscal Year-End of Option Awards Granted in Prior Fiscal Years that Failed to Meet Applicable Vesting Conditions During Fiscal Year | - | - |
| Compensation Actually Paid | 340,452 | 279,558 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.